Setup, so nobody has to ask: orforglipron · a C18 column · semaglutide.
I suspect the honest answer is that it depends, in which case I would like to know on what.
Assume I can obtain either option without difficulty, so availability is not the deciding factor.
Is there a defensible reason to prefer one, or is this a coin flip?
The relevant detail is that the most important parameter is the one that is almost never specified: the gradient slope during the region where your main peak elutes.
System suitability checks on replicate injections of a known standard establish whether the method was in control — if the peak area varies by more than two per cent between replicates, something is wrong.
| Test | Answers | Does NOT answer |
|---|---|---|
| RP-HPLC, area % | What fraction of detected material is the target | How much target is present |
| Quantified content | Milligrams of peptide per vial | What the impurities are |
| ESI-MS identity | Whether the molecular weight matches | Purity, or isomeric substitution |
| Peptide mapping | Sequence, localised to a fragment | Quantity |
| Karl Fischer | Water content of the solid | Solvent content |
| LAL endotoxin | Pyrogen load in EU/mg | Sterility |
| Sterility test | Growth in defined media over 14 days | Endotoxin, or bioburden count |
The underlying point is that formic acid is the compromise when you need the mass spectrometer on the same run, but the peak shape penalty is real and easily a tenth of a per cent on purity.
Peptide impurities from solid-phase synthesis include deletion sequences, truncations from premature cleavage, racemised residues from epimerisation and oxidised variants, each of which may have different chromatographic behaviour.
The limitation is that co-elution is invisible — if two species happen to have the same retention time, they will report as a single peak at their combined area.
If two labs give different numbers, the method difference is the first hypothesis, not lab quality.
HPLC purity, identity confirmation and quantified content on the vial you actually hold. Reports arrive with the chromatogram attached, not just a number.
Submit a sampleFounded 1998. ISO 9001 and cGMP certified, 1,500+ staff and 200+ patents. The synthesis house behind a great many of the vials that get sent out for testing - batch-specific documentation with every order.
Visit GL BiochemWorth being precise here: system suitability is the part of a report that tells you whether the method was under control on the day you were tested, and its absence is concerning.
Reverse-phase stationary phases use C18 or C8 chains bonded to silica, and the pore size of the silica matters more for a peptide of this chain length than the ligand length does.
Acetonitrile is the organic modifier of choice because it has a good UV cutoff, a reasonable viscosity and a refractive index that minimises baseline noise.
I would caution against over-interpreting small differences between runs, because the noise floor of the method is larger than most people assume.
The practical summary: specify the method, run the same method on every sample you compare, and use orthogonal techniques to confirm the result.
edited 15 Jul 2025 by Dr_Tomas_Kral — added the citation requested in comments
In practice, the limit of this technique for these molecules is reaching a point where small improvements require proportionally large investments in method development.
Temperature affects both the viscosity of the mobile phase and the dynamics of molecular interactions, and a method developed at 25 degrees and run at 40 degrees will not behave identically.
Mechanically, detector linearity is why a heavily loaded peak can give false purity by compressing the main peak height while leaving impurity shoulders unchanged.
The selectivity of a reverse-phase separation depends on the hydrophobicity of the side-chain profile, which is why two peptides can co-elute even if they differ by a residue.
One qualification: the limit of detection on a reversed-phase HPLC is set by the noise on the baseline, which for these molecules is usually in the range of a tenth of one per cent or less, and anything smaller is not reproducibly detectable.
Ask for the chromatogram and the system suitability data, not just the number.
Put another way, method transfer between laboratories is almost impossible without full documentation, which is why two labs reporting the same preparation should expect disagreement.
Proline-rich sequences are particularly problematic because the isomerisation kinetics are in the same timescale as the separation, leading to split or broadened peaks at low temperature.
The resolving power of a separation is quantified by the resolution parameter R, defined from the heights and widths of adjacent peaks, and pharmacopoeial methods typically demand R greater than 1.5 for a method to be considered validated.
If two labs give different numbers, the method difference is the first hypothesis, not lab quality.
More usefully, the method is the measurement in reverse-phase chromatography, more so than in almost any other analytical domain, and two methods that look identical can easily produce different results.
Wider-pore phases — 300 Angstrom rather than 100 Angstrom — have faster mass transfer and narrower peaks for peptides above three kilodaltons, which is almost every peptide you will see.
Inter-laboratory studies using identical methods on identical material show precision well within half a per cent when the method is locked down, pointing to method variability as the primary source of disagreement.
The practical summary: specify the method, run the same method on every sample you compare, and use orthogonal techniques to confirm the result.
Ask PeptideStack is a static archive. Posting is closed, but the norms are worth stating: answer the question that was asked, show your working, cite the trial or the certificate, and say plainly where the evidence runs out.